Literature DB >> 11197301

Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression.

J Tang1, C Rivers, E Karita, C Costello, S Allen, P N Fultz, E E Schoenbaum, R A Kaslow.   

Abstract

Variability in the natural history of HIV-1 infection has been repeatedly associated with genetic variants in the beta-chemokine receptor 5 (CCR5) locus. While CCR5 coding sequences have demonstrated relatively limited variation, sequences of its promoter appear polymorphic in all major populations. Our studies revealed five major CCR5 promoter alleles with distributions that differed widely among the four distinct ethnic groups from Kigali, Rwanda and Bronx, New York. In particular, promoter allele P*0103 (G59029-T59353-T59356-A59402-C59653) was largely restricted to black subjects. The promoter allele P*0202 (A59029-C59353-C59356-A59402-T59653) was tightly linked to the slightly less frequent CCR2b-641, a variant of the CCR2b gene, which is about 12.7 kbp upstream from the promoter region. Another closely related promoter allele P*0201 (A59029-C59353-C59356-A59402-C59653) exclusively carried the far less common CCR5-delta 32, a 32-bp deletion in the CCR5 coding sequence 2 kbp downstream from the promoter. The homozygous P*0201/*0201 genotype can be predicted as a risk factor for more rapid disease progression. Among human, chimpanzee, pig-tailed macaque, and sooty mangabey promoter allelic sequences, the apparent ancestral lineage of the promoter sequence (G59029-T59353-C59356-A59402-C59653 = human P*0102) was highly conserved across the primate species analyzed here while P*0201 and P*0202 arose more recently than the other three major alleles. Further effort to establish the mechanism by which CCR chemokine receptor polymorphisms govern the initiation and pathogenesis of primate lentivirus infection apparently requires fully detailed genotypic characterization of the affected populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11197301     DOI: 10.1038/sj.gene.6363640

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  9 in total

1.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.

Authors:  M Tevfik Dorak; Gbolahan O Folayan; Santosh Niwas; Dirk J van Leeuwen; Leland J Yee; Jianming Tang; Richard A Kaslow
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.

Authors:  Florian Hladik; Huanliang Liu; Emily Speelmon; Devon Livingston-Rosanoff; Sean Wilson; Polachai Sakchalathorn; Yon Hwangbo; Benjamin Greene; Tuofu Zhu; M Juliana McElrath
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women.

Authors:  Koushik Chatterjee; Collet Dandara; Margaret Hoffman; Anna-Lise Williamson
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

Review 5.  Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis.

Authors:  H Garg; R Blumenthal
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

6.  Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.

Authors:  Julie M Decker; Kenneth P Zammit; Juliet L Easlick; Mario L Santiago; Denise Bonenberger; Beatrice H Hahn; Olaf Kutsch; Frederic Bibollet-Ruche
Journal:  Virology       Date:  2009-09-12       Impact factor: 3.616

7.  Frequency of long-term nonprogressors in HIV-1 seroconverters From Rakai Uganda.

Authors:  Oliver Laeyendecker; Andrew D Redd; Tom Lutalo; Ronald H Gray; Maria Wawer; Victor Ssempijja; Jordyn Gamiel; John Baptist Bwanika; Fred Makumbi; Fred Nalugoda; Pius Opendi; Godfrey Kigozi; Anthony Ndyanabo; Boaz Iga; Noah Kiwanuka; Nelson Sewankambo; Steven J Reynolds; David Serwadda; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

8.  Interleukin-10 (IL-10) pathway: genetic variants and outcomes of HIV-1 infection in African American adolescents.

Authors:  Sadeep Shrestha; Howard W Wiener; Brahim Aissani; Wei Song; Aditi Shendre; Craig M Wilson; Richard A Kaslow; Jianming Tang
Journal:  PLoS One       Date:  2010-10-14       Impact factor: 3.240

9.  Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconverters.

Authors:  Romina Soledad Coloccini; Dario Dilernia; Yanina Ghiglione; Gabriela Turk; Natalia Laufer; Andrea Rubio; María Eugenia Socías; María Inés Figueroa; Omar Sued; Pedro Cahn; Horacio Salomón; Andrea Mangano; María Ángeles Pando
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.